If FDA determines after approval that the requirements established in § 314.520 , § 314.530 , or § 314.550 are no longer necessary for the safe and effective use of a drug product, it will so notify the applicant. Ordinarily, for drug products approved under § 314.510 , these requirements will no longer apply when FDA determines that the required postmarketing study verifies and describes the drug product's clinical benefit and the drug product would be appropriate for approval under traditional procedures. For drug products approved under § 314.520 , the restrictions would no longer apply when FDA determines that safe use of the drug product can be assured through appropriate labeling. FDA also retains the discretion to remove specific postapproval requirements upon review of a petition submitted by the sponsor in accordance with § 10.30 .
21 CFR Part 314 · Applications for FDA Approval to Market a New Drug
§ 314.560 Termination of requirements
Independent copy, not an official legal edition. 21 CFR is a U.S. Government work in the public domain; this text comes from the eCFR and the annual CFR edition, and may lag recent amendments. The authoritative version is on ecfr.gov. Compliome is not affiliated with or endorsed by FDA. Not legal advice.
FDA guidance that cites § 314.560
- Accelerated Approval – Expedited Program for Serious Conditions draft 5 Dec 2024
- Labeling for Human Prescription Drug and Biological Products Approved Under the Accelerated Approval Regulatory Pathway 4 Feb 2019
- Product Development Under the Animal Rule 2 Oct 2015
Amendment history
Federal Register documents that created or amended this section.
- 50 FR 7493 22 Feb 1985
- 67 FR 37995 31 May 2002